How to buy vTv Therapeutics stock | $2.15

vTv Therapeutics Inc is a biotechnology business based in the US. vTv Therapeutics shares (VTVT) are listed on the NASDAQ and all prices are listed in US Dollars. vTv Therapeutics employs 26 staff and has a trailing 12-month revenue of around USD$22,000.

How to buy shares in vTv Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for vTv Therapeutics. Find the stock by name or ticker symbol: VTVT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until vTv Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.15, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of vTv Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of vTv Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

vTv Therapeutics share price

Use our graph to track the performance of VTVT stocks over time.

vTv Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-02.

Latest market close	USD$2.15
52-week range	USD$1.47 - USD$4.19
50-day moving average	USD$1.7749
200-day moving average	USD$2.1898
Wall St. target price	USD$7
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.563

Buy vTv Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy vTv Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of vTv Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

vTv Therapeutics price performance over time

Historical closes compared with the close of $2.15 from 2020-12-09

1 week (2021-01-12)	N/A
1 month (2020-12-23)	3.37%
3 months (2020-10-19)	N/A
6 months (2020-07-19)	N/A

1 year (2020-01-19)	N/A
2 years (2019-01-19)	N/A
3 years (2018-01-19)	N/A
5 years (2016-01-19)	N/A

vTv Therapeutics financials

Revenue TTM	USD$22,000
Gross profit TTM	USD$-12,355,000
Return on assets TTM	-155.17%
Return on equity TTM	0%
Profit margin	0%
Book value	$-1.673
Market capitalisation	USD$145.7 million

TTM: trailing 12 months

Shorting vTv Therapeutics shares

There are currently 2.1 million vTv Therapeutics shares held short by investors – that's known as vTv Therapeutics's "short interest". This figure is 8% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting vTv Therapeutics shares can be evaluated.

vTv Therapeutics's "short interest ratio" (SIR)

vTv Therapeutics's "short interest ratio" (SIR) is the quantity of vTv Therapeutics shares currently shorted divided by the average quantity of vTv Therapeutics shares traded daily (recently around 902524.13793103). vTv Therapeutics's SIR currently stands at 2.32. In other words for every 100,000 vTv Therapeutics shares traded daily on the market, roughly 2320 shares are currently held short.

However vTv Therapeutics's short interest can also be evaluated against the total number of vTv Therapeutics shares, or, against the total number of tradable vTv Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case vTv Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 vTv Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.1266% of the tradable shares (for every 100,000 tradable vTv Therapeutics shares, roughly 127 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against vTv Therapeutics.

Find out more about how you can short vTv Therapeutics stock.

vTv Therapeutics share dividends

We're not expecting vTv Therapeutics to pay a dividend over the next 12 months.

vTv Therapeutics share price volatility

Over the last 12 months, vTv Therapeutics's shares have ranged in value from as little as $1.47 up to $4.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while vTv Therapeutics's is -2.115. This would suggest that vTv Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, vTv Therapeutics has bucked the trend.

vTv Therapeutics overview

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Frequently asked questions

• What percentage of vTv Therapeutics is owned by insiders or institutions?

  Currently 69.921% of vTv Therapeutics shares are held by insiders and 8.303% by institutions.

• How many people work for vTv Therapeutics?

  Latest data suggests 26 work at vTv Therapeutics.

• When does the fiscal year end for vTv Therapeutics?

  vTv Therapeutics's fiscal year ends in December.

• Where is vTv Therapeutics based?

  vTv Therapeutics's address is: 3980 Premier Drive, High Point, NC, United States, 27265

• What is vTv Therapeutics's ISIN number?

  vTv Therapeutics's international securities identification number is: US9183851057

• What is vTv Therapeutics's CUSIP number?

  vTv Therapeutics's Committee on Uniform Securities Identification Procedures number is: 918385105